What is liver stiffness measurement (LSM)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

What is LSM (Liver Stiffness Measurement)?

LSM (Liver Stiffness Measurement) is a noninvasive imaging-based technique that quantifies the elastic/shear modulus of liver parenchyma to estimate the stage of liver fibrosis, serving as a surrogate marker for fibrosis severity and portal hypertension in patients with chronic liver disease. 1

Technical Overview

LSM is obtained through three primary elastography modalities:

  • Transient Elastography (TE)/Vibration-Controlled Transient Elastography (VCTE): The most widely used method, generating mechanical vibrations through the liver parenchyma 2, 1
  • Shear Wave Elastography (SWE): Uses acoustic vibrations (also called acoustic radiation force impulse or ARFI) 1
  • Magnetic Resonance Elastography (MRE): Generates mechanical vibrations with MRI-based assessment, appearing to be the most accurate method 1

How VCTE Works

VCTE applies a probe to the intercostal skin (9th-11th intercostal space) at a depth of 25-65 mm (M-probe) or 35-75 mm (XL-probe) below the skin surface. A minimum of 10 valid measurements are required to derive a composite score, with adequate quality defined as ≥10 validated measurements and an interquartile range/median value ≤30%. 2

Results are reported in kilopascals (kPa), with a measurement range of 2.5-75 kPa 2.

Diagnostic Performance

The 2025 AASLD systematic review of 240 studies with 61,193 patients demonstrated 1:

  • Significant fibrosis (F2-4): Sensitivity 51-95%, Specificity 36-100%
  • Advanced fibrosis (F3-4): Sensitivity 70-100%, Specificity 74-100%
  • Cirrhosis (F4): Sensitivity 60-100%, Specificity 67-99%

Accuracy increases progressively from F2-4 to F3-4 and is highest for F4 (cirrhosis). 1 For hepatitis C specifically, VCTE demonstrates superior sensitivity (0.89) and specificity (0.91) compared to blood-based tests like APRI and FIB-4 for diagnosing cirrhosis 2.

Critical Limitations and Confounders

LSM values can be falsely elevated by factors unrelated to fibrosis 1:

  • Active hepatitis/inflammation
  • Vascular congestion (congestive heart failure)
  • Recent food intake (within 2-3 hours)
  • Obstructive cholestasis
  • Acute alcohol consumption

Technical failure occurs in 3-4% of examinations and unreliable results in 15-17% of cases. 3 The most important determinants of failure are:

  • BMI >30 kg/m² (especially waist circumference): Odds ratio 7.5 for failure 3
  • Operator experience <500 examinations: Odds ratio 2.5 3
  • Age >52 years: Odds ratio 2.3 3

The XL probe improves success rates in obese patients (95% vs 81% with M probe) but remains less accurate when BMI exceeds 35 kg/m² 4.

Dynamic Changes and Prognostic Value

LSM is not static—it can improve or worsen with disease activity and treatment. 5, 6, 7, 8

  • A 20% increase in LSM at any time is associated with ~50% increased risk of hepatic decompensation (HR 1.58) and liver-related death (HR 1.45) 8
  • Regression to LSM <10 kPa in patients with compensated advanced chronic liver disease reduces liver-related event risk by 75% (HR 0.25) 7
  • In NAFLD, weight loss ≥1 kg significantly reduces LSM (3.6 kPa reduction vs 0.53 kPa in non-losers) 5
  • Successful antiviral therapy (SVR in hepatitis C, long-term nucleos(t)ide analogues in hepatitis B) significantly lowers LSM values 6

Disease-Specific Cutoffs

Cutoff values vary by liver disease etiology and should not be universally applied. 1 Common thresholds include:

  • <10 kPa: Generally excludes advanced fibrosis in most etiologies 7, 8
  • ≥10 kPa: Defines compensated advanced chronic liver disease (cACLD) 7, 8
  • **<20 kPa**: Baveno VI criteria for ruling out varices needing treatment (when platelets >150 G/L) 2, 9
  • ≥15.2 kPa: Optimal cutoff for cirrhosis in hepatitis D (sensitivity 91%, specificity 84%) 10

Clinical Application

LSM should be repeated serially rather than relying on a single measurement, particularly in NAFLD where values fluctuate with lifestyle modifications 5, 7. A single measurement of 12.0 kPa is not reliable for diagnosing advanced fibrosis in NAFLD—repeat testing after 6-12 months is recommended 5.

LSM dynamics provide superior prognostic information compared to single time-point measurements (AUROC 0.933 vs 0.846 for predicting decompensation within 12 months) 8.

References

5
Research

When the liver gets stiff, the tough get moving.

Journal of gastroenterology and hepatology, 2020

Related Questions

What are the clinical implications of a FibroScan liver stiffness measurement of 287 kilopascals?
What does a FibroScan showing liver stiffness of 8.2 kPa and CAP score of 260 dB/m indicate, and what management is recommended?
What does a Median Liver EQI (Elastography Quality Index) of 4.43 kPa indicate about my liver health?
What does a mild FibroScan (liver stiffness < 7 kPa) result indicate and how should it be managed?
What is the management plan for an adult patient with a liver stiffness measurement of 9.9 kPa, indicating significant liver fibrosis, and a history of liver disease, such as hepatitis or alcohol use disorder, diagnosed via liver ultrasound?
Should secondary prophylaxis with penicillin for rheumatic heart disease be continued when the patient is started on piperacillin for another infection?
Can radiation therapy be given before initiating teclistamab?
What is the recommended meropenem dosing, duration, and renal dose adjustments for treating infections caused by CTX-M–producing organisms?
How should I switch a patient from sertraline to lamotrigine?
What is the recommended intravenous dosing regimen for tigecycline, including loading dose, maintenance dose, adjustments for severe hepatic impairment (Child‑Pugh class C) and intermittent hemodialysis, and typical treatment duration?
Is psychosis a disease or a symptom of an underlying disorder?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.